DANIEL L. KISNER - 14 Jun 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Jun 2022
Net transactions value: -$40.4
Form type: 4
Filing time: 16 Jun 2022, 21:53:28 UTC
Previous filing: 03 Jun 2022
Next filing: 17 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZYNE	Common Stock	Award	$0	+23,109	+462%	$0.000000	28,109	14 Jun 2022	Direct	F1
transaction	ZYNE	Common Stock	Sale	$40.4	-40	-0.14%	$1.01	28,069	14 Jun 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZYNE	Stock Option (right to buy)	Award	$0	+34,663		$0.000000	34,663	14 Jun 2022	Common Stock	34,663	$1.01	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.
F2	This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3	The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.